CG Oncology (CGON) Income from Continuing Operations (2023 - 2026)
CG Oncology posted quarterly Income from Continuing Operations of 60101000.0 for Q1 2026, down 74.42% year-on-year from 234982430.16 in Q1 2025, and down 45.68% on a QoQ basis from 41256000.0 in Q4 2025.
CG Oncology (CGON) has 4 years of Income from Continuing Operations data on file, last reported at 60101000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 74.42% year-over-year to 60101000.0; the trailing twelve-month figure through Mar 2026 stood at 186487000.0 (down 76.64% YoY), and the FY2025 full-year result was 160843000.0, down 82.69% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 60101000.0, down from 41256000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 8675000.0 in Q1 2023 and bottomed at 60101000.0 in Q1 2026.
- The 4-year median for Income from Continuing Operations is 20403000.0 (2024), against an average of 27502076.92.
- Peak annual rise in Income from Continuing Operations reached 29.72% in 2025, while the deepest fall reached 119.05% in 2025.
- A 4-year view of Income from Continuing Operations shows it stood at 16551000.0 in 2023, then sank by 92.16% to 31804000.0 in 2024, then dropped by 29.72% to 41256000.0 in 2025, then sank by 45.68% to 60101000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 60101000.0 (Q1 2026), 41256000.0 (Q4 2025), and 43708000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | CG Oncology | 5.01 Bn | 5.01 Bn | -1.88 Mn | -60.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.10 Mn |
| Dec 31, 2025 | -41.26 Mn |
| Sep 30, 2025 | -43.71 Mn |
| Jun 30, 2025 | -41.42 Mn |
| Mar 31, 2025 | -34.46 Mn |
| Dec 31, 2024 | -31.80 Mn |
| Sep 30, 2024 | -20.40 Mn |
| Jun 30, 2024 | -18.91 Mn |
| Mar 31, 2024 | -16.93 Mn |
| Dec 31, 2023 | -16.55 Mn |
| Sep 30, 2023 | -11.76 Mn |
| Jun 30, 2023 | -11.56 Mn |
| Mar 31, 2023 | -8.68 Mn |